Gemphire Therapeutics Inc

Most Recent

  • uploads///cells __
    Company & Industry Overviews

    What’s behind Gemphire Therapeutics’ Stock Price Rise

    On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7.

    By Daniel Collins
  • uploads///drugs _
    Company & Industry Overviews

    Why Gemphire Therapeutics Stock Is Rising Today

    Yesterday, Gemphire Therapeutics (GEMP) announced that its Phase 2b INDIGO-1 trial evaluating investigational first-in-class oral therapy, gemcabene, achieved its primary endpoint.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.